BioSpace News Archive

Combination of CAR-T cell therapy with CARVac highlights the value of cross-platform synergies to address key development challenges in the treatment of cancer

GRAVITAS-301 results show that treatment with itacitinib in combination with corticosteroids did not statistically improve overall response rate or non-relapse mortality compared to placebo plus corticosteroids

The Maryland-based urgent care company offers simple, practical steps for the best protection against the highly-contagious influenza virus

Asklepios BioPharmaceutical (AskBio), a fully integrated, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Sheila Mikhail, AskBio’s Chief Executive Officer and Co-founder, has been invited to provide an overview of the company at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, in San Francisco.

Former Woodland Fire Chief Takes Over for Retiring Chief Gary Fredericksen

The Columbus Organization, a leading provider of case management services for individuals with Intellectual and Developmental Disabilities, today announced that Jeff Klimaski has been appointed CEO and President.

ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, MD, the Company’s Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference.

Adamas grants Sandoz license for its generic version of GOCOVRI® as of March 4, 2030 – over 12 years post GOCOVRI launch

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has provided Salix Pharmaceuticals Ltd. (Salix) with a notice of termination of their 2014 license agreement and has regained the worldwide exclusive rights to RHB-106,